UNSPSC 51323008: Levocarnitine tartrate

This classification denotes a nutritional supplement with the molecular formula C7H15NO3.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4D8F2Q45LQ. Most nations, for tariff and trade purposes, schedule levocarnitine tartrate under HS 29239000 and SITC 51481. As of Q4 2014, LEVOCARNITINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: C[N+](C)(C)C[C@@H](CC(=O)[O-])O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51323008 Levocarnitine tartrate is a Commodity code encompassing a single pharmaceutical product supplied to state and local health agencies, emergency medical services, and institutional healthcare purchasers. Recent solicitations show state and local governments acquiring levocarnitine tartrate as part of broader advanced life support medication portfolios, hospital pharmacy stocking programs, and multi-source generic pharmaceutical cooperative contracts. The code reflects procurement of this specific pharmaceutical line item—used in cardiology, nephrology, and critical care—through both direct vendor supply agreements and wholesaler-mediated distribution channels. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing organizations; the activity spans emergency medical services purchasing at the city level, state-level pharmacy benefit program development, and regional cooperative pharmaceutical procurement at the multistate level.

Recent activity shows geographic spread across Florida, Texas, Minnesota, and Oregon. The City of Tampa Fire Rescue issued an IFB (Bid No. 26P00188) in April 2026 for advanced life support medications including multiple line items, with an estimated contract value of $40,000 and a response deadline of April 8, 2026; the Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer pharmacy benefit programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in multiple jurisdictions including Oregon, with proposals due March 26, 2026. The MMCAP cooperative spans state agencies and local government health facilities across participating states, suggesting levocarnitine tartrate demand clusters within institutional and emergency medical service supply chains managed through both direct procurement and cooperative purchasing vehicles.